The European Medicines Agency (EMA) is continuing to accelerate innovation in animal healthcare, with its 2025 veterinary approvals reflecting strong momentum across poultry vaccines, companion animal therapeutics, livestock disease prevention, and aquaculture solutions. The latest wave of approvals underscores the industry’s growing emphasis on preventive medicine, biologics, recombinant technologies, and advanced therapies designed to improve animal welfare and production efficiency.
Poultry health emerged as one of the most active segments in the EMA’s 2025 approvals. Eco Animal Health received authorization for Ecovaxxin MS, a live vaccine containing Mycoplasma synoviae strain K5885A for chickens, aimed at addressing respiratory and production-related infections in poultry operations.
Further strengthening the poultry vaccine landscape, Merck Animal Health secured approval for Innovax-ND-IBD-ILT, targeting avian infectious laryngotracheitis in chickens. The company also expanded its Nobilis Multriva portfolio with several multivalent vaccines, including:
- Nobilis Multriva REOm
- Nobilis Multriva Gm+REOm
- Nobilis Multriva IBm+ND
- Nobilis Multriva IBm+ND+EDS
- Nobilis Multriva IBm+ND+Gm+REOm+EDS
These combination vaccines are designed to simplify immunization schedules while delivering broader disease protection for commercial poultry producers.
Meanwhile, Boehringer Ingelheim Animal Health strengthened its recombinant vaccine portfolio with approvals for VAXXITEK H5 and Vaxxitek HVT+IBD+H5. Both vaccines use turkey herpesvirus vector technology engineered to provide protection against Newcastle disease, infectious bursal disease, and avian influenza subtype H5.
Ceva Santé Animale also expanded its poultry and cattle vaccine pipeline with approvals for CEVAC REOMUNE for chickens and Bluevac-3 for cattle, alongside Hepizovac, developed to target epizootic haemorrhagic disease virus in cattle.
In the livestock segment, Aquilon Cyl received approval for BioBhyo, containing Brachyspira hyodysenteriae for pigs, reinforcing ongoing efforts to strengthen disease management in swine production. Additionally, Laboratorios Syva S.A. secured approvals for Syvazul BTV 3 and its recombinant protein-based epizootic haemorrhagic disease vaccine for cattle, highlighting continued investment in infectious disease prevention for ruminants.
Companion animal health also saw significant advancements in 2025. Zoetis gained approvals for Lenivia (izenivetmab) for dogs and Portela (relfovetmab) for cats, reflecting the growing adoption of monoclonal antibody therapies in veterinary medicine.
Similarly, Elanco Animal Health expanded its companion animal portfolio with approvals for Zenrelia (ilunocitinib) for dogs, Varenzin for cats, and Elmaro for both dogs and cats. Merck Animal Health also strengthened its pet healthcare business with approvals for Numelvi (atinvicitinib), BRAVECTO CombiUNO, and Fluralaner Intervet for dogs.
Additional companion animal approvals included:
- Prevestrus vet from Vetcare Oy and Lelypharma for dogs
- Emevet and Firocoxib CP-Pharma from CP-Pharma Handelsgesellschaft mbH for dogs
- Omeprazole TriviumVet from TriviumVet for dogs
The EMA’s 2025 approvals also reflected growing attention toward aquaculture and cross-species therapeutics. Vethellas obtained authorization for Prazivetin for fish, while Motion Equity Partners received approval for Hemosyvet, intended for use across cats, chickens, dogs, goats, horses, and pigs.
Collectively, the EMA’s 2025 veterinary approvals demonstrate how the animal health industry is rapidly evolving through recombinant vaccines, biologics, monoclonal antibodies, and advanced preventive therapies. As infectious disease pressures, food security concerns, and pet healthcare demands continue to rise globally, these approvals are expected to play a critical role in shaping the next generation of veterinary medicine.
